Zenas BioPharma, Inc.
ZBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.01 | 0.27 | 0.00 |
| FCF Yield | -35.01% | -4.44% | -9.85% |
| EV / EBITDA | -0.14 | -24.15 | -8.29 |
| Quality | |||
| ROIC | -52.30% | -81.35% | -152.27% |
| Gross Margin | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.82 | 0.55 |
| Growth | |||
| Revenue 3-Year CAGR | – | 3,683,931.50% | -100.00% |
| Free Cash Flow Growth | -292.21% | 54.98% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 1.95 | 1.32 | 0.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -45,654.31 | -17,429.56 | -27,211.22 |